GenScript will use the technology to enhance its gene and cell therapy research, specifically for use with its proprietary oligonucleotide and gene synthesis technologies. The company plans to expand its portfolio to include synthetic single guide RNAs, guide RNA plasmids, and guide RNA libraries, as well as cell line engineering services.

ERS Genomics holds exclusive worldwide licenses from co-founder and recent Nobel prize winner Emmanuelle Charpentier, PhD, to the foundational intellectual property covering CRISPR/Cas9. Financial details of the deal were not disclosed.

CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies
CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies...

GenScript, Singapore's EDDC partner on antifibrosis antibody development
GenScript ProBio is collaborating with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development,...

GenScript supports InnoBation's development of CAR T therapies
GenScript Biotech has signed an agreement with InnoBation for cell line development and engineering and manufacturing services for InnoBation's good manufacturing...

Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with...